Vigonvita Life Sciences Cash Flow Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Net Income	-355.72	-211.4	12.09
Depreciation & Amortization	37.1	32.85	16.82
Other Amortization	1.94	0.77	0.02
Loss (Gain) From Sale of Assets	-	0.04	-
Loss (Gain) From Sale of Investments	0.71	-0.22	-
Stock-Based Compensation	184.17	14.75	14.75
Provision & Write-off of Bad Debts	3.18	2.79	2.4
Other Operating Activities	15.2	9.84	1.29
Change in Accounts Receivable	4.32	25.85	-28.05
Change in Inventory	-3.4	-0.08	-2.11
Change in Accounts Payable	35.85	8.7	16.7
Change in Unearned Revenue	-9.18	-1.41	5.53
Change in Other Net Operating Assets	-10.83	8.68	-8.77
Operating Cash Flow	-96.67	-108.85	30.67
Capital Expenditures	-159.97	-77.68	-86.72
Sale (Purchase) of Intangibles	-3.83	-10.47	-26.13
Investment in Securities	-70.17	0.22	-
Other Investing Activities	-	-0.48	-48.02
Investing Cash Flow	-233.97	-88.41	-160.87
Long-Term Debt Issued	540.05	263.18	172.35
Long-Term Debt Repaid	-330.55	-178.86	-84.05
Net Debt Issued (Repaid)	209.5	84.32	88.3
Issuance of Common Stock	535.27	160	-
Other Financing Activities	-84.44	-22.14	-11.8
Financing Cash Flow	660.33	222.18	76.5
Foreign Exchange Rate Adjustments	-2.85	0.24	0.25
Net Cash Flow	326.84	25.16	-53.46
Free Cash Flow	-256.64	-186.53	-56.05
Free Cash Flow Margin	-251.38%	-1576.46%	-28.07%
Free Cash Flow Per Share	-1.68	-1.28	-0.39
Cash Interest Paid	19.41	14.79	11.8
Cash Income Tax Paid	0.21	-	-
Levered Free Cash Flow	-113.64	-141.47	-
Unlevered Free Cash Flow	-105.29	-131.36	-
Change in Working Capital	16.75	41.74	-16.7